In the first years of ATIA’s existence, the foundation -Stichting Valorisation Bridge- was financed by a mix of public and private funding to:
Set up and expand the Alan Turing Institute Almere
Research and develop the HeMAS technology.
After the initial phase of applied research, demonstrating and piloting, ATIA is now in the phase of product & service development and has entered the market of health and life sciences as a private company.
ATIA it is well positioned to benefit from the opportunity represented by the changing paradigm in health care towards personalized medicine and the market demands for advanced analytics products and services.
ATIA is looking for impact-first-investors who want to optimize social impact with a floor of financial returns.
For more information regarding investment opportunities please contact us.